Evaluation of hypertensive cardiac abnormalities using the cornell product

Circulation Journal

Volumn 71, Issue 5, 2007, Pages 731-735

  Shirai, Tetsuro ^a   Kasao, Masashi ^a   Nozaki, Miho ^a   Nitta, Syuuya ^a  

^a TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

Author keywords

Cornell product; Hypertension; Left ventricular hypertrophy

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORNELL PRODUCT; DIGITAL IMAGING; DISEASE MARKER; DOPPLER ECHOCARDIOGRAPHY; ELECTRIC POTENTIAL; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PARTITION COEFFICIENT; QRS COMPLEX; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED;

EID: 34247571511     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.731     Document Type: Article

References (25)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275: 1571-1576.
2. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: The Hisayama study. Arch Intern Med 2003; 163: 361-366.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
4. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-1076.
5. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
6. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 26: 4-11.
7. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
8. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
9. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol 2001; 38: 1829-1835.
10. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. Am J Hypertens 2003; 16: 895-899.
11. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hender T, Ibsen H, et al. The Losartan Intervention for Endpoint reduction (LIFE) in Hypertension study: Rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 705-713.
12. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
13. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-690.
14. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1153.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
16. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865-875.
17. Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, et al. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: The LIFE study. Am J Hypertens 2002; 15: 663-671.
18. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25: 417-423.
19. Okin PM, Roman MJ, Devereux RB, Kligfield P. Time-voltage area of the QRS for the identification of left ventricular hypertrophy. Hypertension 1996; 27: 251-258.
20. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Blood Pressure 2001; 10: 74-82.
21. Oki T, Tabata T, Yamada H, Wakatsuki T, Shinohara H, Nishikado A, et al. Clinical application of pulsed Doppler tissue imaging for assessing abnormal left ventricular relaxation. Am J Cardiol 1997; 79: 921-928.
22. The J-ELAN Investigators. Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): Rationale and design. Circ J 2006; 70: 124-128.
23. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-690.
24. Okin PM, Devereux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: The LIFE study. J Hum Hypertens 2004; 18: 403-409.
25. Conrady AO, Rudomanov OG, Zaharov DV, Iakovleva OI, Ovchinnicova OA, Vahrameeva NV, et al. Prospective study of the changes in left ventricular mass and geometry patterns in hypertensive patients during 5 years of follow-up. Circ J 2005; 69: 11374-1379.